

February 24, 2012
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

SymBio Announces Bendamustine Hydrochloride (SyB L-0501) Launch in Taiwan

TOKYO, Japan, February 24, 2011 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, President & CEO: Fuminori Yoshida, "SymBio") announced that its licensing partner, InnoPharmax, Inc. (Headquarters: Taipei, Taiwan, "InnoPharmax"), has launched bendamustine HCl (SyB L-0501) under the trade name Innomustine[®] in Taiwan for the treatment of chronic lymphocytic leukemia (CLL) and low-grade non-Hodgkin's lymphoma (NHL) as monotherapy in patients.

InnoPharmax received approval of its New Drug Application (NDA) for bendamustine HCl (SyB L-0501) from the Taiwan Food and Drug Administration (TFDA) in October, 2011. In Japan, SymBio received market approval of bendamustine HCl (SyB L-0501) under the trade name TREAKISYM[®] in October, 2010, and launched the drug in December for the treatment of patients with refractory/relapsed low-grade non-Hodgkin's lymphoma and mantle cell lymphoma. Working with Eisai Co. Ltd., TREAKISYM[®] has achieved rapid market penetration in Japan.

SyB L-0501 is being marketed in other Asia Pacific countries after receiving market approvals in Hong Kong (December, 2009) and Singapore (January, 2010) for the treatment of patients with low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia, and in South Korea (May, 2011) for the treatment of patients with chronic lymphocytic leukemia and multiple myeloma.

Aspiring to be a leading oncology specialty Pharma in Asia Pacific, SymBio's business in key Asian markets continues to expand as it nimbly develops and commercializes SyB L-0501 in the hematology space to address the underserved medical needs of patients.

[Please see the following for further information on bendamustine hydrochloride and SymBio]

[Contact]

Hiroki Maekawa

Board Director, Corporate Officer, Chief Financial Officer

Tel: +081(0)3 5472 1125

Note to Editors

Glossary

1 Non-Hodgkin's Lymphoma: is a diverse group of blood cancers that include any kind of lymphoma, except Hodgkin's lymphomas, in which B or T white blood cells (lymphocytes) develop malignant growths - the majority of Japanese patients suffer from non-Hodgkin's lymphomas. The disease is categorized by progression and has been divided into low-grade (slow-growing) and intermediate to high-grade (fast-growing) types. The number of low-grade non-Hodgkin's lymphoma patients in Japan is estimated to be around 11,000, including 4,000 refractory/relapsed patients and 7,000 untreated patients.

2 Chronic Lymphocytic Leukemia: is a type of blood cancer characterized by a progressive accumulation of functionally incompetent lymphocytes (a type of white blood cell) in bone marrow. The number of chronic lymphocytic leukemia patients in Japan is estimated to be around 2,000, or 3% of all leukemia patients, and is much lower than in the U.S. where it comprises an estimated 30% of all leukemia patients.

About Bendamustine Hydrochloride (SyB L-0501)

Bendamustine was first synthesized in the early 1960s in former 'East Germany' by Jenapharm, and is currently marketed in Germany under the brand name "Ribomustin[®]" as a treatment for non-Hodgkin's lymphoma, multiple myeloma and chronic lymphocytic leukemia. Mundipharma has received market authorizations in a number of EU countries for bendamustine under the brand name "Levact[®]". In the United States, the drug has been approved by the U.S. Food and Drug Administration and is marketed as TREANDA[®] for the treatment of chronic lymphocytic leukemia and relapsed and refractory low-grade B-cell non-Hodgkin's lymphoma. SymBio Pharmaceuticals Limited originally acquired the exclusive right from Astellas Deutschland GmbH (Headquarters: Munich, Germany, formerly Astellas Pharma GmbH) to develop and commercialize bendamustine in Japan (December, 2005), followed by signature of a second license agreement for the exclusive right to China/Hong Kong, Taiwan, South Korea and Singapore (March, 2007).

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Ltd. was established in March, 2005 by Fuminori Yoshida, who previously served concurrently as Corporate VP of Amgen Ltd. and founding President of Amgen Japan (currently Takeda Bio Development Center Limited). The company's underlying corporate mission is "delivering hope to patients in need" as it aspires to be a leading specialty pharmaceutical company in Asia Pacific dedicated to addressing underserved medical needs in the areas of oncology, hematology and autoimmune disease.